JP2012503674A - 抗癌剤との補助的治療薬としての下垂体アデニル酸シクラーゼ活性化ポリペプチド（ｐａｃａｐ）及びｐａｃａｐ類似体の使用 - Google Patents

抗癌剤との補助的治療薬としての下垂体アデニル酸シクラーゼ活性化ポリペプチド（ｐａｃａｐ）及びｐａｃａｐ類似体の使用 Download PDF

Info

Publication number
JP2012503674A
JP2012503674A JP2011529275A JP2011529275A JP2012503674A JP 2012503674 A JP2012503674 A JP 2012503674A JP 2011529275 A JP2011529275 A JP 2011529275A JP 2011529275 A JP2011529275 A JP 2011529275A JP 2012503674 A JP2012503674 A JP 2012503674A
Authority
JP
Japan
Prior art keywords
pacap
compound
subject
administered
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2011529275A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012503674A5 (enExample
Inventor
ミン、リ
ジェローム、エル．マダードラット
デイビッド、エイチ．コイ
ベチヒ、バトゥマン
Original Assignee
ジ アドミニストレーターズ オブ ザ トゥレーン エデュケーショナル ファンド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ジ アドミニストレーターズ オブ ザ トゥレーン エデュケーショナル ファンド filed Critical ジ アドミニストレーターズ オブ ザ トゥレーン エデュケーショナル ファンド
Publication of JP2012503674A publication Critical patent/JP2012503674A/ja
Publication of JP2012503674A5 publication Critical patent/JP2012503674A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
JP2011529275A 2008-09-25 2009-09-25 抗癌剤との補助的治療薬としての下垂体アデニル酸シクラーゼ活性化ポリペプチド（ｐａｃａｐ）及びｐａｃａｐ類似体の使用 Pending JP2012503674A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US19416608P 2008-09-25 2008-09-25
US61/194,166 2008-09-25
PCT/US2009/058445 WO2010036936A2 (en) 2008-09-25 2009-09-25 Use of pituitary adenylate cyclase-activating polypeptide (pacap) and pacap analogs as adjunctive treatments with anticancer agents

Publications (2)

Publication Number Publication Date
JP2012503674A true JP2012503674A (ja) 2012-02-09
JP2012503674A5 JP2012503674A5 (enExample) 2013-11-28

Family

ID=42060409

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011529275A Pending JP2012503674A (ja) 2008-09-25 2009-09-25 抗癌剤との補助的治療薬としての下垂体アデニル酸シクラーゼ活性化ポリペプチド（ｐａｃａｐ）及びｐａｃａｐ類似体の使用

Country Status (7)

Country Link
US (1) US20110268789A1 (enExample)
EP (1) EP2337577A4 (enExample)
JP (1) JP2012503674A (enExample)
CN (1) CN102215859B (enExample)
AU (1) AU2009296456B2 (enExample)
CA (1) CA2738549A1 (enExample)
WO (1) WO2010036936A2 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5908406B2 (ja) 2009-11-02 2016-04-26 ジ アドミニストレーターズ オブ ザ トゥレーン エデュケーショナル ファンド 下垂体アデニル酸シクラーゼ活性化ポリペプチド（ｐａｃａｐ）の類似体およびその使用方法
CA2788835A1 (en) * 2010-02-05 2011-08-11 The Administrators Of The Tulane Educational Fund The use of pituitary adenylate cyclase-activating polypeptide (pacap) and pacap analogs as adjunctive treatments with inhibitors of calcineurin or inhibitors of the mammalian target of rapamycin (mtor) complexes
US9353171B2 (en) * 2011-11-17 2016-05-31 The Administrators Of The Tulane Educational Fund Use of pituitary adenylate cyclase-activating polypeptide (PACAP) and PACAP analogs for treating contrast-induced nephropathy
CN103145851B (zh) * 2013-02-22 2014-07-02 暨南大学 重组蛋白PACAP38-NtA及其编码基因与应用
WO2018129200A2 (en) 2017-01-05 2018-07-12 The Regents Of The University Of California Pac1 receptor agonists (maxcaps) and uses thereof
ES2677242B1 (es) * 2017-01-31 2019-03-27 Univ Alcala Henares Nanoconjugados formados por moléculas dendríticas y péptidos como agentes antitumorales frente al cáncer
JP7695772B2 (ja) * 2017-11-14 2025-06-19 千寿製薬株式会社 Ｐａｃａｐの安定化ペプチド
JPWO2020230869A1 (enExample) * 2019-05-14 2020-11-19
DE102024001175A1 (de) * 2024-04-04 2025-10-09 ReViSan Healthcare GmbH Zubereitung zur Behandlung von entzündlichen Erkrankungen der Atemwege.

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005538942A (ja) * 2002-05-03 2005-12-22 ニューロノヴァ アーベー 成体の神経幹又は前駆体細胞に関するｐａｃａｐ、ｖｉｐ及びマキサディランの機能的役割及び治療への使用可能性
JP2008501723A (ja) * 2004-06-11 2008-01-24 ベクタス・バイオシステムズ・リミテッド 循環器病の治療のための組成物および方法
JP2008507540A (ja) * 2004-07-21 2008-03-13 チューレン ユニバーシティ ヘルス サイエンス センター Ｐａｃａｐ化合物を用いる腎臓機能障害及び多発性骨髄腫の治療

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2008303956A1 (en) * 2007-09-11 2009-04-02 Mondobiotech Laboratories Ag Proadrenomedullin alone or in combination with big gastrin I as a therapeutic agent

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005538942A (ja) * 2002-05-03 2005-12-22 ニューロノヴァ アーベー 成体の神経幹又は前駆体細胞に関するｐａｃａｐ、ｖｉｐ及びマキサディランの機能的役割及び治療への使用可能性
JP2008501723A (ja) * 2004-06-11 2008-01-24 ベクタス・バイオシステムズ・リミテッド 循環器病の治療のための組成物および方法
JP2008507540A (ja) * 2004-07-21 2008-03-13 チューレン ユニバーシティ ヘルス サイエンス センター Ｐａｃａｐ化合物を用いる腎臓機能障害及び多発性骨髄腫の治療

Also Published As

Publication number Publication date
AU2009296456A1 (en) 2010-04-01
WO2010036936A9 (en) 2010-07-15
EP2337577A1 (en) 2011-06-29
WO2010036936A2 (en) 2010-04-01
CN102215859B (zh) 2016-04-20
CN102215859A (zh) 2011-10-12
US20110268789A1 (en) 2011-11-03
EP2337577A4 (en) 2012-08-15
AU2009296456B2 (en) 2016-06-16
CA2738549A1 (en) 2010-04-01

Similar Documents

Publication Publication Date Title
JP5908406B2 (ja) 下垂体アデニル酸シクラーゼ活性化ポリペプチド（ｐａｃａｐ）の類似体およびその使用方法
AU2009296456B2 (en) Use of pituitary adenylate cyclase-activating polypeptide (PACAP) and PACAP analogs as adjunctive treatments with anticancer agents
EP1877435B1 (en) Glucagon-like-peptide-2 (glp-2) analogues
US20160122406A1 (en) Analogs of pituitary adenylate cyclase-activating polypeptide (pacap) and methods for their use
CN108431021B (zh) 具有神经元损失预防和再生效果的肽以及包含该肽的组合物
US9597371B2 (en) Prominin-1 peptide fragments and uses thereof
US20120309683A1 (en) USE OF PITUITARY ADENYLATE CYCLASE-ACTIVATING POLYPEPTIDE (PACAP) AND PACAP ANALOGS AS ADJUNCTIVE TREATMENTS WITH INHIBITORS OF CALCINEURIN OR INHIBITORS OF THE MAMMALIAN TARGET OF RAPAMYCIN (mTOR) COMPLEXES
US20110251126A1 (en) Intestinal treatment
US20130045922A1 (en) Pro-angiogenic fragments of prominin-1 and uses thereof
KR20220145888A (ko) 선택적 gip 수용체 작용제로서의 펩티드
EP1778268B1 (en) Treatment of renal dysfunction and multiple myeloma using pacap compounds
US9353171B2 (en) Use of pituitary adenylate cyclase-activating polypeptide (PACAP) and PACAP analogs for treating contrast-induced nephropathy
HK1108898B (en) Glucagon-like-peptide-2 (glp-2) analogues
HK1154872A (en) Glucagon-like-peptide-2 (glp-2) analogues

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20120925

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20131007

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20131217

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20140317

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140325

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140617

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20140617

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20150123

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150525

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20150526

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20150724

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20150911